Briacell Therapeutics Corp (BCTX)

$3.76 -0.16 (-4.08%)
Market Cap 28.42M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 181,800
Avg Vol 509,814
Day's Range N/A - N/A
Shares Out 7.25M
Stochastic %K 12%
Beta 1.42
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
dhadad64
dhadad64 Feb. 23 at 9:18 PM
$BCTX what šŸ’©
1 Ā· Reply
JediGreen
JediGreen Feb. 23 at 7:13 PM
$BCTX My taxes are about to be paid on 100K in profits from last year that I have in this and it all comes down to phase 3 readout if Iā€™ll be burned and wasted 20k in tax money. Tick tock my position is locked in and be a miracle if the company was bought out in the billions of dollars. ļæ¼ļæ¼ļæ¼
1 Ā· Reply
JediGreen
JediGreen Feb. 23 at 7:06 PM
$BCTX As we sit and wait for phase 3 readout.
0 Ā· Reply
MollyWantsACracker
MollyWantsACracker Feb. 23 at 7:04 PM
$BCTX Added some here. My ave is $3.80.
1 Ā· Reply
Kirubin
Kirubin Feb. 23 at 4:45 PM
$BCTX šŸ˜¬šŸ˜¬šŸ˜¬šŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļø
0 Ā· Reply
TWBXX
TWBXX Feb. 21 at 8:47 PM
$BCTX Why this matters for Phase 3 OS If a therapy: Shrinks distant tumors Activates systemic immunity Has almost no toxicity Shows a 32% 2ā€‘year survival tail in Phase 2 ā€¦then the OS signal in Phase 3 is not random noise ā€” itā€™s mechanistically anchored. This is exactly why the FDA allowed a single Phase 3 OS trial for registration.
0 Ā· Reply
TWBXX
TWBXX Feb. 21 at 8:46 PM
$BCTX Mechanistic meaning: systemic immunity, not local effect When a local injection shrinks distant tumors, it means: The immune system is being primed against tumor antigens Activated Tā€‘cells are circulating The therapy is functioning as a broad antiā€‘tumor vaccine This is the same mechanistic pattern that turned checkpoint inhibitors into multiā€‘billionā€‘dollar drugs ā€” but Briaā€‘IMT does it with: Minimal toxicity No systemic cytokine storms No need for radiation or chemotherapy to ā€œprimeā€ the immune system This is why the Phase 2 survival tail was so strong.
0 Ā· Reply
JediGreen
JediGreen Feb. 20 at 11:30 PM
$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/
0 Ā· Reply
Rohtan
Rohtan Feb. 20 at 3:32 PM
$BCTX see you guys below 3 soon
2 Ā· Reply
JediGreen
JediGreen Feb. 20 at 3:32 PM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html
1 Ā· Reply
Latest News on BCTX
BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 5 days ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 5 days ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 6 days ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 26 days ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Wed, 28 Jan 2026 07:30:00 -0500 - 26 days ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 27 days ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Tue, 27 Jan 2026 07:30:00 -0500 - 27 days ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 5 weeks ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

2026-01-16T13:58:57.000Z - 5 weeks ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Thu, 15 Jan 2026 16:05:00 -0500 - 5 weeks ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:36:30.000Z - 5 weeks ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T11:19:44.000Z - 5 weeks ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T10:55:53.000Z - 5 weeks ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

2026-01-14T06:56:44.000Z - 5 weeks ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

2026-01-14T06:35:20.000Z - 5 weeks ago

BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

BriaCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

2026-01-14T06:35:20.000Z - 5 weeks ago

BriaCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 5 weeks ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T20:32:32.000Z - 5 weeks ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T14:08:02.000Z - 5 weeks ago

BriaCell Surge Above 50%; What's The Buzz?

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

2026-01-13T12:53:09.000Z - 5 weeks ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTSā„¢ Patient

Tue, 13 Jan 2026 07:30:00 -0500 - 5 weeks ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTSā„¢ Patient

ā€œEleven clinical trials that will shape medicine in 2026ā€ ā€“ BriaCell Phase 3 Trial Featured in Nature Medicine

Thu, 18 Dec 2025 07:30:00 -0500 - 2 months ago

ā€œEleven clinical trials that will shape medicine in 2026ā€ ā€“ BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

2025-12-10T13:29:00.000Z - 2 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCSĀ® 2025

Wed, 10 Dec 2025 07:30:00 -0500 - 2 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCSĀ® 2025

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

2025-12-09T13:34:16.000Z - 2 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Tue, 09 Dec 2025 07:30:00 -0500 - 2 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

2025-12-02T12:50:27.000Z - 2 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCSĀ® 2025

Tue, 02 Dec 2025 07:30:00 -0500 - 2 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCSĀ® 2025

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

2025-12-01T12:53:14.000Z - 3 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCSĀ® 2025

Tue, 25 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCSĀ® 2025

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

2025-11-20T13:28:07.000Z - 3 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Thu, 20 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCSĀ® 2025

Tue, 18 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCSĀ® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ā„¢ at SITC 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ā„¢ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ā„¢ in Breast and Prostate Cancer Models

Tue, 04 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ā„¢ in Breast and Prostate Cancer Models

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-28T08:01:00.000Z - 4 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Top 3 Earnings Acceleration Buys for November

2025-10-27T19:05:00.000Z - 4 months ago

Top 3 Earnings Acceleration Buys for November

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

2025-10-22T12:51:17.000Z - 4 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Wed, 22 Oct 2025 07:30:00 -0400 - 4 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T20:52:14.000Z - 4 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T13:25:38.000Z - 4 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

2025-10-21T12:50:54.000Z - 4 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Tue, 21 Oct 2025 07:50:00 -0400 - 4 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ā„¢ for Breast Cancer

Tue, 21 Oct 2025 07:30:00 -0400 - 4 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ā„¢ for Breast Cancer

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

2025-10-20T13:31:42.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Mon, 20 Oct 2025 07:30:00 -0400 - 4 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

2025-10-13T13:27:39.000Z - 4 months ago

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Mon, 13 Oct 2025 07:30:00 -0400 - 4 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+ā„¢ Preclinical Data at SITC 2025 Annual Meeting

Fri, 03 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell to Present Bria-OTS+ā„¢ Preclinical Data at SITC 2025 Annual Meeting

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

2025-09-12T16:00:02.000Z - 5 months ago

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

BriaCell's Bria-OTS+ā„¢ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 6 months ago

BriaCell's Bria-OTS+ā„¢ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ā„¢ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 6 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ā„¢ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 6 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ā„¢ for Cancer

Aug 13, 2025, 7:30 AM EDT - 6 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ā„¢ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 7 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 7 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 7 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 15, 2025, 7:30 AM EDT - 7 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

BriaCell's Bria-IMTā„¢ Demonstrates Survival Advantage over TrodelvyĀ® and Control Group in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-IMTā„¢ Demonstrates Survival Advantage over TrodelvyĀ® and Control Group in Metastatic Breast Cancer

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in ā€œEye-Bulgingā€ Breast Cancer Patient

Jul 10, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in ā€œEye-Bulgingā€ Breast Cancer Patient

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTSā„¢ Metastatic Breast Cancer Study

Jul 9, 2025, 7:30 AM EDT - 8 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTSā„¢ Metastatic Breast Cancer Study

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 8, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jul 2, 2025, 7:30 AM EDT - 8 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 24, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 4, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Jun 2, 2025, 7:30 AM EDT - 9 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

BriaCell Bria-OTSā„¢ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 27, 2025, 7:30 AM EDT - 9 months ago

BriaCell Bria-OTSā„¢ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 23, 2025, 7:30 AM EDT - 9 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

BriaCell CEO Letter to Shareholders

May 20, 2025, 7:30 AM EDT - 9 months ago

BriaCell CEO Letter to Shareholders

BriaCell Reports ā€œLate-Breakerā€ Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 30, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports ā€œLate-Breakerā€ Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 4:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+ā„¢ Development

Apr 28, 2025, 7:30 AM EDT - 10 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+ā„¢ Development

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 8:00 PM EDT - 10 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 10:11 AM EDT - 10 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTSā„¢

Apr 24, 2025, 7:30 AM EDT - 10 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTSā„¢

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 23, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

dhadad64
dhadad64 Feb. 23 at 9:18 PM
$BCTX what šŸ’©
1 Ā· Reply
JediGreen
JediGreen Feb. 23 at 7:13 PM
$BCTX My taxes are about to be paid on 100K in profits from last year that I have in this and it all comes down to phase 3 readout if Iā€™ll be burned and wasted 20k in tax money. Tick tock my position is locked in and be a miracle if the company was bought out in the billions of dollars. ļæ¼ļæ¼ļæ¼
1 Ā· Reply
JediGreen
JediGreen Feb. 23 at 7:06 PM
$BCTX As we sit and wait for phase 3 readout.
0 Ā· Reply
MollyWantsACracker
MollyWantsACracker Feb. 23 at 7:04 PM
$BCTX Added some here. My ave is $3.80.
1 Ā· Reply
Kirubin
Kirubin Feb. 23 at 4:45 PM
$BCTX šŸ˜¬šŸ˜¬šŸ˜¬šŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļøšŸ¤·šŸ½ā€ā™‚ļø
0 Ā· Reply
TWBXX
TWBXX Feb. 21 at 8:47 PM
$BCTX Why this matters for Phase 3 OS If a therapy: Shrinks distant tumors Activates systemic immunity Has almost no toxicity Shows a 32% 2ā€‘year survival tail in Phase 2 ā€¦then the OS signal in Phase 3 is not random noise ā€” itā€™s mechanistically anchored. This is exactly why the FDA allowed a single Phase 3 OS trial for registration.
0 Ā· Reply
TWBXX
TWBXX Feb. 21 at 8:46 PM
$BCTX Mechanistic meaning: systemic immunity, not local effect When a local injection shrinks distant tumors, it means: The immune system is being primed against tumor antigens Activated Tā€‘cells are circulating The therapy is functioning as a broad antiā€‘tumor vaccine This is the same mechanistic pattern that turned checkpoint inhibitors into multiā€‘billionā€‘dollar drugs ā€” but Briaā€‘IMT does it with: Minimal toxicity No systemic cytokine storms No need for radiation or chemotherapy to ā€œprimeā€ the immune system This is why the Phase 2 survival tail was so strong.
0 Ā· Reply
JediGreen
JediGreen Feb. 20 at 11:30 PM
$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/
0 Ā· Reply
Rohtan
Rohtan Feb. 20 at 3:32 PM
$BCTX see you guys below 3 soon
2 Ā· Reply
JediGreen
JediGreen Feb. 20 at 3:32 PM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html
1 Ā· Reply
tbagoni
tbagoni Feb. 20 at 3:14 PM
$BCTX No volume making this look bad!
1 Ā· Reply
IChiGOdoranZ
IChiGOdoranZ Feb. 19 at 7:30 PM
$BCTX strengthens oncology pipeline as sub BriaPro Therapeutics secures exclusive worldwide rights to sCD80, a novel immunotherapy licensed from shown to stop tumor growth in preclinical studies. BriaCell commits up to $3M to accelerate development. https://globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html
0 Ā· Reply
Rohtan
Rohtan Feb. 19 at 6:53 PM
$BCTX 1 cent up 10 cents down. $3 soon
1 Ā· Reply
Kirubin
Kirubin Feb. 19 at 3:55 PM
$BCTX Get them boys! Time to recoverā€¦should be good on the way UP!šŸ‘šŸ½šŸ‘šŸ½šŸ‘šŸ½šŸ«” Done with this one!
0 Ā· Reply
IChiGOdoranZ
IChiGOdoranZ Feb. 19 at 3:19 PM
Cancer Stock News: $BCTX News Alert: BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License for the Treatment of Cancer. Strong anti-tumor activity of sCD80 has been reported in multiple tumor types. Dive into the news here https://globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html
0 Ā· Reply
IChiGOdoranZ
IChiGOdoranZ Feb. 19 at 2:25 PM
$BCTX strengthens oncology pipeline as sub BriaPro Therapeutics secures exclusive worldwide rights to sCD80, a novel immunotherapy licensed from shown to stop tumor growth in preclinical studies. BriaCell commits up to $3M to accelerate development. https://globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html
1 Ā· Reply
SmallCapVoice
SmallCapVoice Feb. 19 at 1:36 PM
$BCTX strengthens its oncology pipeline as subsidiary BriaPro Therapeutics Corp. secures exclusive worldwide rights to sCD80, a novel immunotherapy licensed from University of Maryland, Baltimore County shown to stop tumor growth in preclinical studies. BriaCell also commits up to $3M to accelerate development. Big step expanding its immunotherapy platform. https://www.globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html
0 Ā· Reply
JediGreen
JediGreen Feb. 19 at 5:50 AM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html
0 Ā· Reply
RJ5x2
RJ5x2 Feb. 18 at 11:38 PM
$BCTX if youā€™re investing or interested in, watch the video fam:
1 Ā· Reply
RJ5x2
RJ5x2 Feb. 18 at 10:39 PM
$BCTX https://finance.yahoo.com/news/briacell-briapro-enter-asset-purchase-223000000.html
1 Ā· Reply
RJ5x2
RJ5x2 Feb. 18 at 10:34 PM
$BCTX idk about all that bro. Youā€™re going to at least double your investment, if you bought anywhere from $5-$15 ok? Turn off the notifications
1 Ā· Reply
TWBXX
TWBXX Feb. 18 at 4:22 PM
$BCTX 2. Fully Diluted Shares (if all warrants/options convert) BriaCell has a stack of warrants from past financings. When you include all warrants + options + RSUs: āœ” ~3.0ā€“3.3 million fully diluted (Depending on which warrant tranches you count ā€” some are far outā€‘ofā€‘theā€‘money.) This is not the number used for market cap, but it is relevant for buyout modeling.
1 Ā· Reply